UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Clinical cancer research, 2013-09, Vol.19 (17), p.4559-4563

2013

Link zum Volltext

Verfügbarkeit prüfen

Issues in Using Progression-Free Survival When Evaluating Oncology Products

Journal of clinical oncology, 2009-06, Vol.27 (17), p.2874-2880

2009

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

The oncologist (Dayton, Ohio), 2014-01, Vol.19 (1), p.94-99

2014

Link zum Volltext

Verfügbarkeit prüfen

Design and Analysis of Non-Inferiority Trials

1, 2016

Link zum Volltext

Verfügbarkeit prüfen

Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek

Clinical trials (London, England), 2023-08, Vol.20 (4), p.341-350

2023

Link zum Volltext

Verfügbarkeit prüfen

Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents in Patients with Cancer

Clinical cancer research, 2008-06, Vol.14 (11), p.3242-3247

2008

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

Clinical cancer research, 2012-06, Vol.18 (12), p.3212-3217

2012

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Clinical cancer research, 2010-09, Vol.16 (17), p.4331-4338

2010

Link zum Volltext

Verfügbarkeit prüfen

Some essential considerations in the design and conduct of non-inferiority trials

Clinical trials (London, England), 2011-08, Vol.8 (4), p.432-439

2011

Link zum Volltext

Verfügbarkeit prüfen

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation

Therapeutic innovation & regulatory science, 2023-01, Vol.57 (1), p.109-120

2023

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia

The oncologist (Dayton, Ohio), 2011-01, Vol.16 (1), p.97-104

2011

Link zum Volltext

Verfügbarkeit prüfen

Inferences on a life distribution by sampling from the ages or the ages at death

Lifetime data analysis, 2006-09, Vol.12 (3), p.305-323

Rothmann, Mark D

2006

Link zum Volltext

Verfügbarkeit prüfen

Missing Data in Biologic Oncology Products

Journal of biopharmaceutical statistics, 2009-11, Vol.19 (6), p.1074-1084

2009

Link zum Volltext

Verfügbarkeit prüfen

On Non-inferiority Analysis Based On Delta-method Confidence Intervals

Journal of biopharmaceutical statistics, 2003-08, Vol.13 (3), p.565-583

2003

Link zum Volltext

Verfügbarkeit prüfen

Statement on P-values

Statistics in biopharmaceutical research, 2021-02, Vol.13 (1), p.57-58

2021

Link zum Volltext

Verfügbarkeit prüfen

Stability of maxima over randomly deleted sets

Statistics & probability letters, 1997-12, Vol.36 (2), p.145-152

Rothmann, Mark D.

1997

Link zum Volltext

Verfügbarkeit prüfen

Stochastic processes involving random deletion

Journal of applied probability, 2001-03, Vol.38 (1), p.95-107

2001

Link zum Volltext

Verfügbarkeit prüfen

Weak convergence on randomly deleted sets

Journal of applied probability, 1998-12, Vol.35 (4), p.893-902

1998

Link zum Volltext

Verfügbarkeit prüfen

A Law of Large Numbers on Randomly Deleted Sets

The Annals of applied probability, 1997-02, Vol.7 (1), p.170-182

1997

Link zum Volltext

Verfügbarkeit prüfen

Persistent convergence on randomly deleted sets

Statistics & probability letters, 1994-08, Vol.20 (5), p.367-373

1994

Link zum Volltext

Verfügbarkeit prüfen

A series criterion for moving maxima

Stochastic processes and their applications, 1993-06, Vol.46 (2), p.241-247

1993

Link zum Volltext

Verfügbarkeit prüfen

Strong limiting bounds for a sequence of moving maxima

Statistics & probability letters, 1991-05, Vol.11 (5), p.403-410

1991

Link zum Volltext

Verfügbarkeit prüfen

Missing Data and Analysis Sets

Design and Analysis of Non-Inferiority Trials, 2012, p.198-223

2012

Link zum Volltext

Verfügbarkeit prüfen

Non-Inferiority Trial Considerations

Design and Analysis of Non-Inferiority Trials, 2012, p.32-59

2012

Link zum Volltext

Verfügbarkeit prüfen

Strength of Evidence and Reproducibility

Design and Analysis of Non-Inferiority Trials, 2012, p.60-73

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Englisch
(54)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Life Sciences & Biomedicine
(34)
Clinical Trials
(17)
Humans
(16)
Medical Informatics
(15)
Biology, Life Sciences
(14)
Epidemiology & Medical Statistics
(14)
Mathematics
(14)
Physical Sciences
(14)
Statistics & Probability
(12)
United States
(9)
United States Food And Drug Administration
(9)
Drug Approval
(8)
Female
(8)
Oncology
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Antineoplastic Agents
(6)
Cattle
(6)
Exact Sciences And Technology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Issues in Using Progression-Free Survival When Evaluating Oncology Products

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

Design and Analysis of Non-Inferiority Trials

Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek

Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents in Patients with Cancer

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Some essential considerations in the design and conduct of non-inferiority trials

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation

U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia

Inferences on a life distribution by sampling from the ages or the ages at death

Missing Data in Biologic Oncology Products

On Non-inferiority Analysis Based On Delta-method Confidence Intervals

Statement on P-values

Stability of maxima over randomly deleted sets

Stochastic processes involving random deletion

Weak convergence on randomly deleted sets

A Law of Large Numbers on Randomly Deleted Sets

Persistent convergence on randomly deleted sets

A series criterion for moving maxima

Strong limiting bounds for a sequence of moving maxima

Missing Data and Analysis Sets

Non-Inferiority Trial Considerations

Strength of Evidence and Reproducibility

Suchergebnisse filtern